norganic NO 2 − (nitrite) undergoes reactions that yield vasodilatory products that contribute to blood pressure (BP) regulation and hypoxic signaling.
of NO 3 − is reduced in the oral cavity by commensal bacteria, xanthine oxidoreductase can reduce NO 3 − to NO 2 − . 9 Up to 25% of plasma NO 3 − can be stored and concentrated by the salivary glands, thus, providing a facile route for entero-salivary recycling. [10] [11] [12] [13] Also acquired from both endogenous ˙NO oxidation reactions and dietary sources, the more intrinsically-reactive NO 2 − can undergo multiple reactions, such as protonation to HNO 2 (nitrous acid) in the low pH environments of the gastrointestinal tract, inflammatory foci, and the mitochondrial intermembrane compartment. Nitrite is also absorbed into the circulation and tissues where it can react with (1) deoxyhemoglobin and other heme proteins and molybdopterin-containing enzymes to form ˙NO [14] [15] [16] [17] or (2) heme peroxidases to yield the nitrating species nitrogen dioxide (˙NO 2 ). 18 During intermediary metabolism and inflammatory responses, partially reduced oxygen species, such as superoxide (O 2˙− ), H 2 O 2 (hydrogen peroxide), and lipid peroxyl radicals will also undergo a variety of reactions with ˙NO and NO 2 − to accelerate the rates of production of nitrosating (addition of ˙NO) and nitrating (addition of ˙NO 2 ) species. 19 ˙NO, NO 2 − , and HNO 2 will also undergo a variety of reactions that lead to the generation of symmetric and asymmetric dinitrogen trioxide (ONONO and OONNO). 20, 21 These unstable intermediates rapidly decay to yield secondary nitrosating and nitrating species, as well as ˙NO. These and other redox reactions are responsible for propagating downstream signaling and pathogenic responses that are a consequence of oxidative, nitrosative, and nitrative post-translational protein modification (PTM) reactions.
Human studies and animal models reveal that ≤15 day courses of inorganic and dietary NO 3 − and NO 2 − administration induce robust responses that include decreased BP, 1, 2, 11, 22 hypoxic vasodilation, 1, 23, 24 modulation of mitochondrial function under hypoxic or exercise stress, 25, 26 prevention of endothelial dysfunction, 27 and inhibition of platelet aggregation. 28, 29 It remains uncertain as to whether these effects are mediated by ˙NO, secondary nitrating and nitrosating products or a combination thereof that will induce functionally-significant PTMs, such as thiol S-nitrosation or thiol alkylation. 30, 31 One class of nitrogen oxide metabolites are electrophilic NO 2 -FA (fatty acid nitroalkene derivatives), 32 formed by radical addition reactions of ˙NO 2 with alkenyl carbons of unsaturated fatty acids. Once formed, these lipid electrophiles rapidly • NO 2 (nitration) and NO + (nitrosation) reactions produce an array of bioactive nitrogen oxide products, including NO 2 -FA (fatty acid nitroalkene derivatives) and S-nitrosothiol derivatives that have incompletely-characterized biological activities. B, To understand the metabolism of single doses of heavy nitrogen labeled sodium NO 3 − and NO 2 − and to characterize their signaling pathways and physiological effects, crossover drug design studies were conducted. Ten healthy volunteers were randomized into 1 of the 2 subject cohorts to receive a single dose of each study drug, oral 15 N-labeled sodium NO 3 − react with the nucleophilic amino acid cysteine, and to a lesser extent histidine, residues via reversible Michael addition. 33 Endogenously present at low nM concentrations in healthy human plasma and urine, the rates and extents of production of NO 2 -FA can be increased by an array of metabolic and inflammatory-related nitration reactions ( Figure 1C) . 34 Upon the PTM of functionally-significant hyperreactive cysteine residues in critical enzymes and transcriptional regulatory proteins, NO 2 -FA influence gene expression and inflammatory responses. 35 For example, specific proinflammatory and BP regulation enzymes are directly inhibited by NO 2 -FA, including xanthine oxidoreductase, cyclooxygenase-2, and soluble epoxide hydrolase. [36] [37] [38] Notably, NO 2 -FA mediate pleiotropic signaling actions: this includes the PTM of p65 that inhibits nuclear factor-κB to inhibit proinflammatory cytokine expression, the activation of heat shock factor-1 dependent heat shock protein expression, the partial agonism of peroxisome proliferator-activating receptor-γ, and the activation of nuclear factor (erythroid derived) 2-regulated anti-inflammatory gene expression. [39] [40] [41] [42] [43] The most prevalent endogenous NO 2 -FA, nitro-conjugated linoleic acid (NO 2 -cLA), is detected as both the free acid, complex lipid-esterified, and as protein adducts. 34, 44 cLA (predominantly 18:2, cis-9, trans-11) is a dietary polyunsaturated fatty acid prevalent in dairy products, meats, and plants. Endogenous generation of cLA in humans occurs by the isomerization of bis-allylic linoleic acid to a conjugated diene and by the desaturation of oleic acid to cLA, with both reactions catalyzed by the gut microbiome. 45 Importantly, the external flanking carbons of the conjugated diene of cLA are 3 to 4 orders of magnitude more reactive than bis-allylic linoleic acid. 44 This promotes facile addition reactions of radical species, such as ˙NO 2 to yield NO 2 -cLA. It will always be a daunting challenge to dissect which products of nitrogen oxide metabolism, such as ˙NO, metal-NO complexes, RS-NO (S-nitrosothiols), or NO 2 -FA, are proximally responsible for modulating the physiological actions of nitrogen oxides in humans, such as the regulation of inflammatory responses, BP regulation, and platelet function.
We hypothesized that ingested NO 3 − is reduced to the redoxactive metabolite NO 2 − in vivo, which is then metabolized to both ˙NO and NO 2 -cLA. Because ˙NO and NO 2 -cLA are both signaling molecules known to modulate BP and platelet function, In trial 1, 10 subjects were enrolled. To understand the precise mechanism of how the metabolites signal and exert their effects, these subjects were invited to return to participate in a modified pharmacokinetic study, trial 2, to serve as a direct paired control. Five subjects completed trial 2. Subjects were randomized in both trials as shown in Figure 1B . All study subjects were 18 to 60 years of age and had a normal BP defined as systolic BP (SBP) ≤130 and diastolic BP (DBP) ≤85 mm Hg. The study was approved by the University of Pittsburgh Institutional Review Board and the US FDA for use of these investigational new drugs. Before performing any of the research study procedures or interventions, subjects provided written informed consent, and procedures were followed in accordance with institutional guidelines.
The selected drug doses were 1 g Na , and MetHb (methemoglobin) was assessed using noninvasive co-oximetry (Masimo Corp, Irvine, CA), at times 0 (baseline or trough before study drugs), 0.5, 1, 2, 3, 6, and 24 hours postdrug administration. Before the start of each pharmacokinetic study visit, subjects fasted for 10 to 12 hours. BP and mean arterial pressure were measured for 30 to 45 minutes to ensure subjects were at a steady state before the time-0 mean arterial pressure (MAP) and administration of the study drugs. BP, MAP, respiratory rate, and heart rate monitoring were measured every 15 minutes during the first 2 hours, then at 3, 6, and 24 hours postdrug administration.
To track NO 2 − metabolism in vivo ( Figure 1C ), pharmacokinetic evaluations were used to examine total ( 15 N and 14 N) plasma NO 3 − , NO 2 − , and RS-NO (S-nitrosothiols) by gas-phase reductive ozonebased chemiluminescence detection. 15 NO was differentiated from endogenous 14 NO in blood using electron paramagnetic resonance spectroscopy via the formation of the 15 NO-Hb. This iron-nitrosyl paramagnetic species has a distinctive hyperfine absorbance measured by electron paramagnetic resonance, which produces a doublet for NO-Hb labeled with 15 NO 2 -cLA using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as previously described. 44 A detailed description of the urinary measures is published separately. 34 Platelet activity was monitored at time 0, 6, and 24 hours after 15 N drug with and without cLA. Comprehensive methods are described in the online-only Data Supplement.
Statistical Analysis
Detailed statistical analyses for each data set are included in the individual figure legends. Where differences existed between trial drug treatments, post hoc multiple comparisons were performed using Bonferroni correction. Measurements shown represent mean±SEM. A P value <0.05 was considered significant.
Results

15
NO 3 − / 15 NO 2 − Pharmacokinetics With and Without cLA
Ten healthy adult volunteers (baseline characteristics in Table  S1 in the online-only Data Supplement) who fulfilled the inclusion/exclusion criteria were randomized into 1 of the 2 subject cohorts of 5 subjects to receive a single dose of each study drug, oral Na 15 NO 3 − (1 g), and Na 15 NO 2 − (20 mg) in random order ( Figure 1B ). Pharmacokinetic visits were separated by a 3-to 7-day washout period to ensure washout of nitrogen oxides and metabolites. Total plasma NO 3 − concentrations were significantly increased after 15 Figure 2D ) and returned to basal concentrations after 3 hours.
Five of the 10 healthy volunteers who completed trial 1 returned for trial 2 and were randomized to receive a single dose of each study drug, Na 15 NO 3 − (1 g) and Na 15 NO 2 − (20 mg), plus 3 g cLA, in random order, separated by a 3-to 7-day washout period so that metabolic responses could be compared with those from trial 1 ( Figure 1B Figure S1 ). Whereas total plasma NO 2 − concentrations increased over time after 15 NO 2 − +cLA (P=0.001), a trend toward lower total plasma NO 2 − concentrations was seen at 0.5 and 1 hour ( Figure 2F , closed circles) when compared with 15 NO 2 − alone (P=0.059; Figure 2F , open circles). Peak plasma NO 2 − concentration was 3.0±0.5 μM for 15 
Formation of MetHb and 15 NO-Hb
Further metabolism of 15 NO 2 − was also reflected by MetHb, 15 NO-Hb, plasma RS-NO, and 15 NO 2 -cLA generation ( Figure 1C ). After 15 NO 3 − administration, no significant increase in MetHb was observed ( Figure 3A ). After 15 NO 2 − dosing, a small but significant increase in MetHb occurred from baseline to 1 hour (baseline, 1.2±0.1%; peak at 1 hour, 1.6±0.1%; P<0.001; Figure 3B ) and returned to baseline by 3 hours. cLA supplementation did not impact MetHb levels (not shown). The metabolism of 15 NO 2 − to 15 NO was measured by the formation of 15 NO-Hb in red blood cells sedimented from venipuncture blood samples. A representative electron paramagnetic resonance spectra (gray) shows the hyperfine splitting characteristic of 15 NO-Hb from one subject (raw data in black; Figure 3C ). There was no evidence for the formation of 14 NO-Hb ( Figure S2B ). 15 NOHb formation was only detected between 0.5 and 1 hour after 15 NO 2 − supplementation ( Figure 3D ). 15 NO-Hb derivatives were not detectable after 15 
Formation of RS-NO
Representative plasma RS-NO traces are shown at baseline and for peak concentrations of RS-NO at 0.5 hours after 15 NO 2 − dosing, followed by an additional time point after 15 NO 2 − treatment ( Figure 4A ). 15 NO 2 − consumption significantly increased plasma RS-NO concentrations (baseline, 3.2±1.0 nmol/L; peak concentration of 6.1±1.0 nmol/L at 0.5 hours; P<0.05; Figure 4B ) and returned to basal concentrations after 3 hours. In contrast, after 15 NO 3 − dosing, there was no significant impact on RS-NO concentration ( Figure S3A , open circles). There was also no impact of cLA supplementation on plasma RS-NO concentrations after dosing in combination with either 15 Figure S3A and S3B). Figure 6A and B, open circles) with no differences in heart rate (data not shown). In this 15 NO 2 − -dosed cohort, the reduction in SBP and MAP correlated with the change in plasma NO 3 − concentration ( Figure S4A and S4C) . Also, the greater the reduction in DBP at 1 hour, the greater the rise in total NO 3 − concentration at 0.5 hours ( Figure S4B) . Notably, the significant decreases in SBP and MAP that persisted for ≤2 hours after subjects were treated with 15 NO 2 − were abolished on coadministration of cLA in trial 2 ( Figure 6A and 6B, closed circles) .
Inhibition of platelet activation in whole blood was observed 6 hours after 15 
NO 2
− dosing (baseline, 33.2±7.1%; 6 hours postdosing, 7.8±1.6%; P=0.02; Figure 6C , open bars)-an effect that was eliminated when subjects were dosed with 15 NO 2 − +cLA, ( Figure 6C , dark bars). After 15 NO 3 − dosing in all 10 subjects who completed trial 1, there was significant inhibition of platelet activation 6 hours after 15 NO 3 − administration (baseline, 17.0±4.1%; 6 hours postdosing, 9.0±1.7%; P=0.029; Figure S5A ). With coadministration of 15 NO 3 − +cLA in trial 2, there was no significant inhibition of platelet activation in whole blood at 6 hours (baseline, 27.5±12.3%; 6 hours postdosing, 20.0±7.5%; Figure S5B ).
In subjects given oral 15 NO 3 − , plasma 15 NO 2 − concentrations were significantly increased from 1 to 2 hours post-dosing ( Figure S1 , open circles), with a maximum of 1.40 µmol/L Figure S6B , open circles) with no significant change in SBP and MAP ( Figure S6A and S6C, open circles) or heart rate (data not shown). No significant correlations were noted between changes in SBP, DBP, or MAP and absolute NO 3 − or NO 2 − concentrations after 15 NO 3 − administration (not shown). After 15 NO 3 − +cLA dosing, there were no significant changes in SBP, DBP, and MAP ( Figure S6A through S6C, closed circles) or heart rate (data not shown).
Discussion
There are a panoply of physiological reactions that nitrogen oxides can undergo, all uniquely influenced by factors such as changes in pH, oxygen tension, CO 2 /H 2 CO 3 levels, rates of production of reactive inflammatory mediators, and redoxreactive metalloprotein levels. The relative significance of these mitigating factors will change as basal metabolism transitions to metabolic stress and inflammatory responses. This will critically impact the specific reactions that occur between ˙NO/NO 2 − , molecular oxygen, partially reduced oxygen species, and metal centers. In the context of ˙NO signaling, the physiological outcomes of these reactions are manifested by the diversion of ˙NO away from canonical guanylate cyclase activation and cGMP-dependent signaling responses to the generation of a spectrum of highly reactive and transient secondary oxidizing, nitrosating, and nitrating products ( Figure 1A) . 51 At high concentrations, these reactive products may be pathogenic, but under physiological conditions, these chemically-reactive intermediates (1) represent a metastable ˙NO reserve that still signals via guanylate cyclase activation and cGMP-dependent mechanisms and (2) react with and modify the structure and function of cell targets (eg, unsaturated fatty acids and proteins). These latter reactions instigate an array of PTMs and non-cGMP-dependent signaling responses. 31 In particular, the nucleophilic amino acid cysteine confers proteins with a sensitivity for reduction-oxidation (redox)-induced PTMs that include cysteine oxidation, glutathionylation, S-nitrosation, and alkylation upon Michael addition by electrophilic species. 52 These PTMs intimately link metabolic and inflammatory status with changes in cell and organ function because many enzymes, receptors, and transcriptional regulatory proteins that regulate metabolism and inflammation are endowed with functionally-significant hyperreactive cysteine moieties. Herein, we report that oral coadministration of 3 g of the polyunsaturated fatty acid cLA with 15 Figure 2D ) and gave detectable increases in plasma nitrogen oxide concentrations, with each nitrogen oxide displaying unique pharmacokinetic and metabolite profiles. Moreover, coadministration of cLA significantly affected these parameters. Oral 15 NO 3 − reached its highest plasma NO 3 − concentration 1 hour after dosing and yielded a peak concentration of plasma NO 2 − 2 to 6 hours after dosing (Figure 2A and 2C ). This concentration of plasma NO 2 − with oral 15 NO 3 − was not sufficient to increase MetHb, to yield detectable red blood cell 15 NO-Hb levels ( Figure 3A and 3D ), or to induce ( Figure S6A and S6C) or sustain ( Figure S6B ) reductions in BP parameters. Dosing of 15 NO 3 − in concert with cLA suppressed peak plasma NO 3 − levels by ≈30% ( Figure 2E , closed circles). For oral 15 NO 2 − , the highest plasma concentration of NO 2 − was measured 0.5 hours after dosing ( Figure 2D ), giving a modest but significant increase in plasma NO 3 − metabolite concentrations 2 to 3 hours later ( Figure 2B) . Notably, the coadministration of cLA with 15 NO 2 − also suppressed peak plasma NO 2 − concentrations by ≈30% ( Figure 2F, closed circles) .
Nitrite reacts with oxyHb to form NO 3 − and MetHb and with deoxyhemoglobin to ultimately form NO-Hb 16 . On NO 2 − protonation to HNO 2 and reaction with ˙NO, both symmetric (ONONO) and asymmetric (OONNO) dinitrogen trioxide intermediates are generated, serving as proximal mediators of biomolecule nitrosation and nitration. 20, 62 After 15 NO 2 − administration, evidence of all of these reactions was noted, with a significant 25% increase in MetHb levels, the formation of ≈1 µmol/L paramagnetic 15 NO-Hb species, and a 3 nmol/L increase in mean plasma protein RS-NO levels 0.5 hours postdosing ( Figures 3B, 3D, 4A , and 4B). With cLA supplementation, mean plasma NO 2 -cLA concentration increased by ≈5 nM 34 . Only a few studies have reported changes in plasma ˙NO concentrations at baseline and after dietary NO 3 − − chemistry where HNO 2 in turn gives rise to secondary N 2 O 3 species that mediate nitrosation, nitration, and oxidation of susceptible targets. These reactions can be blunted by administering proton-pump inhibitors, such as esomeprazole, thus, inhibiting gastric acid secretion and NO 2 − protonation to HNO 2 -a pH response that typifies the pharmacological action of proton pump inhibitors. 63 Esomeprazole also inhibited the BP-lowering effects of nitrite. The more basic conditions in the stomach after esomeprazole administration limited the protonation of NO 2 − to HNO 2 -a species that undergoes both dismutation and ˙NO reactions to yield the nitrosating and nitrating products symmetric and asymmetric dinitrogen trioxide (ONONO and ONNOO). 20 The pathways leading to NO 2 -cLA formation first require entero-salivary reduction of NO 3 − to NO 2 − . In the present study, where 15 NO 2 − and 15 NO 3 − were orally consumed in the presence of cLA, stomach pH would either remain the same or be lowered by the acidic cLA (pKa=4.0). The suppression of detectable plasma NO 3 − and NO 2 − by ≈30% with cLA coadministration indicated that the greater availability and reactivity of cLA favored its nitration, thus, supporting the generation of NO 2 -cLA derivatives rather than the accumulation of NO 3 − and NO 2 − in plasma and presumably other tissue compartments. Our present report supports the concept that the addition of cLA and its facile nitration by NO 2 − -derived species is a consequence of these acid-catalyzed reactions. Our data indicate that this concomitantly leads to an attenuation of ˙NO-forming reactions that would otherwise result in the vasodilation and inhibition of platelet function that was observed when − with cLA had no impact on plasma RS-NO levels ( Figure S3A ).
In healthy, hypertensive, and high body mass index subjects, cLA supplementation (3-6.8 g/d; 5-26 weeks) compared with control or placebo displays no significant impact on BP in humans. [64] [65] [66] [67] Herein, we observed that the decreased BP induced by 15 NO 2 − was abrogated by concomitant cLA administration ( Figure 6A and 6B) . In addition to promoting a shift in nitrosative and nitrative chemistries, cLA might also be modulating NO 2 − responses by impacting endogenous ˙NO production. [68] [69] [70] The present data do not diminish the significance of heme proteins, such as deoxyHb, in mediating reactions of NO 2 − that lead to changes in vascular function. Rather, our results further affirm the impact that other biomolecules, such as conjugated diene-containing fatty acids that readily undergo radical addition reactions, can have on nitrogen oxide reaction pathways and downstream signaling responses. This is manifested by the fact that Fe-NO Hb levels in 15 NO 2 − -treated subjects are decreased to undetectable levels with 15 NO 2 − + cLA administration (electron paramagnetic resonance analysis has a limit of quantification of ≈500 nmol/L for Fe-NO complexes). These findings indicate that cLA supplementation and other dietary constituents have the ability to modulate the biochemical reactions of NO 2 − , the trafficking of downstream nitrogen oxide metabolites and the physiological concentrations of this pluripotent signaling mediator. Moreover, a more chronic exposure to elevated cLA and fat in the diet has the potential to also influence the entero-salivary microbiome and its impact on nitrogen oxide metabolism. 71 Along with vasodilatory actions, ˙NO formed by the reduction of NO 2 − inhibits platelet function, including platelet adhesion to the endothelium 47 and platelet aggregation. 72 In contrast, partially reduced oxygen species, such as O 2˙− and H 2 O 2 , propagate platelet activation. 73, 74 The mechanism by which ˙NO affects platelet activity is by activating cGMPdependent signaling. Dietary NO 3 − sources (beetroot juice or KNO 3 − ) reduce platelet activation or aggregation, 11, 29, 75, 76 and NO 2 − in the presence of deoxygenated red blood cells inhibit platelet activation or aggregation. 16, 28, 29, [77] [78] [79] [80] Herein, we confirm that 15 NO 2 − inhibits human platelets in vivo, and note that the inhibition of platelet activation occurred in whole blood for 6 hours after 15 NO 2 − dosing, with the inhibition of platelet activation still evident well beyond the physiological plasma NO 2 − peak and the time of 15 NO-Hb detection. Previous in vitro studies revealed that 2 synthetic NO 2 -FA, nitro-linoleic acid, and nitro-arachidonic acid (at high concentrations in buffered saline) inhibited platelet aggregation and activation, respectively. 81, 82 In the more clinically-relevant study herein, 15 NO 2 − administration in vivo decreased platelet activation in whole blood at 6 hours. The whole-blood basal platelet activation levels of subjects were moderately increased, which are attributed to an artifact of the venipuncture sampling. There may be a threshold plasma NO 2 − concentration where sufficient ˙NO formation subsequently reduces platelet activation with 15 
Study Limitations and Strengths
The data presented here cannot exclude dietary cLA contribution during trial 1 and dietary NO 3 − and NO 2 − contributions also influencing baseline plasma NO 3 − and NO 2 − concentrations in both trials. Additionally, no formal power calculations were performed as these were exploratory phase I studies. Although this study may be underpowered to detect an effect of day, 83, 84 NO 2 − intakes of 0 to 20 mg/day 85 and cLA intakes of 150 to 200 mg/day 86 are low, but daily intakes of ≤2.6 g of cLA are reported in the literature. Therefore, it may be difficult to achieve all 3 of these intakes simultaneously through diet on a daily basis, so as to be comparable with those provided in capsule formulations herein. However, our goal with cLA supplementation was to define whether the biochemical reactions and physiological responses to oral 15 NO 3 − and 15 NO 2 − were modulated by cLA. Our investigations are strengthened by using paired pharmacokinetic studies in the same subjects so direct comparisons could be made using 15 N sodium NO 3 − and NO 2 − with and without cLA supplementation to track ˙NO metabolism and the source of ˙NO and NO 2 -cLA species formation in vivo with each drug.
Perspectives
The oral administration of cLA altered the metabolic fate of oral 15 NO 3 − and 15 NO 2 − and modulated the ˙NO-signaling and vasodilatory properties of these nitrogen oxides. The cGMP-dependent signaling actions of NO 3 − and NO 2 − can be further transformed by digestive reactions, the entero-salivary microbiome and metalloprotein-catalyzed reactions to yield ˙NO and additional nitrogen oxides that elicit redox signaling responses via nitration, nitrosation, and oxidation reactions. One would expect that the spectrum of nitrogen oxide products formed will depend on diet, metabolic and inflammatory status, acidic microenvironments, and NO NO 2 − can be significantly modulated by the composition of the diet, particularly with meat and dairy products that are rich in cLA.
